Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases, and Rheumatoid Arthritis Research and Therapies.
Reducing Early-Life Smoke Exposure as a Preventive Strategy for Pediatric Multiple Sclerosis: Results from the PEDIGREE Study
Correction: Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus
A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study
Risk of pediatric multiple sclerosis (pedMS) associated to ozone exposure. The PEDIGREE study
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
Big Multiple Sclerosis Data network: an international registry research network
Multiple Sclerosis Progression and Relapse Activity in Children
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
Effectiveness of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter, retrospective, real-world sTudY (OPPORTUNITY)
Multiple sclerosis progression: time for a new mechanism-driven framework
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)
Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEQ-IT)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Aggressive multiple sclerosis (1): Towards a definition of the phenotype
Early clinical markers of aggressive multiple sclerosis
Aggressive multiple sclerosis (2): Treatment
Delay from treatment start to full effect of immunotherapies for multiple sclerosis